Versor Investments’s Medifast MED Stock Holding History

Versor Investments’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,943	Closed	-$534K	–	853
2024 Q1	$534K	Buy	13,943 +5,942	+74%	+$288K	0.11%	308
2023 Q4	$538K	Buy	+8,001	New	+$557K	0.11%	314
2023 Q3	–	Sell	-3,343	Closed	-$308K	–	772
2023 Q2	$308K	Sell	3,343 -1,057	-24%	-$94.1K	0.05%	406
2023 Q1	$456K	Buy	+4,400	New	+$488K	0.06%	356
2022 Q4	–	Sell	-4,179	Closed	-$453K	–	872
2022 Q3	$453K	Buy	4,179 +696	+20%	+$99.7K	0.03%	482
2022 Q2	$629K	Buy	+3,483	New	+$623K	0.02%	411
2021 Q2	–	Sell	-2,337	Closed	-$495K	–	380
2021 Q1	$495K	Buy	+2,337	New	+$559K	0.03%	138
2020 Q4	–	Sell	-3,219	Closed	-$529K	–	214
2020 Q3	$529K	Buy	3,219 +790	+33%	+$130K	0.04%	150
2020 Q2	$337K	Sell	2,429 -871	-26%	-$80K	0.03%	126
2020 Q1	$206K	Buy	+3,300	New	+$300K	0.01%	210
2019 Q3	–	Sell	-2,287	Closed	-$293K	–	322
2019 Q2	$293K	Buy	+2,287	New	+$318K	0.02%	248

Other funds holding MED

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Versor Investments's MED Position: Q2 2024 in Review

Versor Investments sold out of Medifast (MED) in Q2 2024, closing a stake of 13,943 shares — an estimated $534K sold.

Versor Investments first reported a position in MED in Q2 2019 and held it in 11 quarters. The position peaked at $629K in Q2 2022. 158 funds tracked by Wall St. Rank hold MED as of Q2 2024.

Versor Investments reported no remaining Medifast position as of Q2 2024 after selling out during the quarter.
Versor Investments sold 13,943 Medifast shares in Q2 2024, an estimated $534K.
Versor Investments first reported a position in Medifast in Q2 2019 and held it in 11 quarters.
Versor Investments's Medifast position peaked at $629K in Q2 2022.
158 funds tracked by Wall St. Rank held Medifast as of Q2 2024.

Based on Versor Investments's 13F filing for Q2 2024, filed 1 Aug 2024.